Why UnitedHealth’s Massive Bottom-Line Beat Doesn’t Matter
UnitedHealth Group released mixed second-quarter financial results and maintained its guidance before the markets opened on Wednesday.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
When UnitedHealth Group Inc. (NYSE: UNH | UNH Price Prediction) released its second-quarter financial results before the markets opened on Wednesday, the firm posted $7.12 in earnings per share (EPS) and $62.1 billion in revenue. Analysts were calling for EPS of $5.18 on $63.43 billion in revenue. In the same period of last year, UnitedHealth said it had $3.60 in EPS and revenue of $60.59 billion.
Earnings were substantially higher than anticipated this quarter due primarily to the unprecedented, temporary deferral of care in the company’s risk-based businesses. However, management was quick to say that this likely will be offset in the quarters ahead.
During the latest quarter, total revenues grew $4.1 billion, or 6.8%, year over year, reflecting balanced, broad-based revenue growth across Optum and UnitedHealthcare.
UnitedHealthcare revenues increased 2.5% year over year to $62.1 billion. Second-quarter earnings from operations at UnitedHealthcare were $9.2 billion, nearly double from the same period last year.
[nativounit]
Optum second-quarter revenues and operating earnings of $32.7 billion and $2.2 billion, respectively, increased from $28.0 billion and $2.1 billion a year ago. This was led by earnings growth at OptumHealth.
Looking ahead, the company maintained its outlook for the 2020 full year. Currently, UnitedHealth expects to see EPS in the range of $16.25 to $16.55. Consensus estimates call for $16.29 in EPS and $258.69 billion in revenue for the full year.
On the books, the company ended the quarter with $25.59 billion in cash and cash equivalents, up from $14.25 billion at the end of 2019.
UnitedHealth stock traded down about 2% to $302.68 early Wednesday, in a 52-week range of $187.72 to $315.84. The consensus price target is $332.44.
[recirclink id=723711][wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
